---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134969"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:44.477075+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss

## Summary
- Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).
- 98% compliance; no serious adverse events reported in CAHmelia-204.
- Phase 2 CAHptain-205 showed trend of larger A4 reductions at higher BID doses; no drug-related SAEs.
- Company discontinuing both trials, winding down tildacerfont investment, and evaluating strategic options.

## SEC filing metadata
- accession: 0000950170-24-134969
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/0000950170-24-134969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/sprb-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134969
- JSON: https://secwatch.observer/filing/0000950170-24-134969.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.